Table 2. Univariate and multivariate analysis for progression-free survival and overall survival

FactorsProgression-free survivalOverall survival
Univariate analysisMultivariate analysisUnivariate analysisMultivariate analysis
HR (95% CI)P valueP valueHR (95% CI)P valueP value
Histologic subtype
Squamous cell carcinoma vs adenocarcinoma0.28 (0.10–0.81)0.010.250.33 (0.10–1.07)0.050.54
PIK3CA
Mutant vs Wild-type0.33 (0.10–1.05)0.050.150.23 (0.05–1.08)0.040.78
PTEN
Altered vs Wild-type3.71e-09 (0–Inf)0.050.413.64e-09 (0–Inf)0.080.77
ERBB3
Mutant vs Wild-type34.9 (3.09–394.00)˂ 0.0010.0119.8 (2.71–144.00)˂ 0.0010.02
PI3K/AKT pathway
Altered vs Wild-type0.33 (0.11–0.94)0.030.090.25 (0.08–0.84)0.020.97
PD-L1 expression
Positive vs negative0.36 (0.11–1.19)0.080.010.31 (0.09–1.06)0.050.02
TMB
≥5 mut/Mb vs<5 mut/Mb0.26 (0.09–0.77)0.010.010.31 (0.09–1.07)0.050.18
  • CI, confidence interval; HR, hazard ratio; mut/Mb, mutations per megabase; PD-L1, programmed death-ligand 1; TMB, tumor mutational burden.